Skip to main content
Veterinary Medicines

TETRAVALENT L-CHP

Authorised
  • Canine distemper virus, strain CDV/WHO 134, Live
  • Canine adenovirus 2, Live
  • Canine parvovirus, strain CPV-N-1988, Live

Product identification

Medicine name:
TETRAVALENT L-CHP
Active substance:
  • Canine distemper virus, strain CDV/WHO 134, Live
  • Canine adenovirus 2, Live
  • Canine parvovirus, strain CPV-N-1988, Live
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Canine distemper virus, strain CDV/WHO 134, Live
    3.00
    log10 cell culture infective dose 50
    /
    1.00
    Dose
  • Canine adenovirus 2, Live
    3.00
    log10 cell culture infective dose 50
    /
    1.00
    Dose
  • Canine parvovirus, strain CPV-N-1988, Live
    3.00
    log10 cell culture infective dose 50
    /
    1.00
    Dose
Pharmaceutical form:
  • Lyophilisate and solvent for suspension for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AI03
Authorisation status:
  • Valid
Authorised in:
  • Romania
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Romvac Company S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Romvac Company S.A.
Responsible authority:
  • Institute For Control Of Biological Products And Veterinary Medicines
Authorisation number:
  • 120233
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Romanian (PDF)
Published on: 21/01/2022
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."